Mode
Text Size
Log in / Sign up
N/A N=1,545 Diagnostic

Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study

Infectious Gastroenteritis

Enrolled (actual)
1,545
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcome: Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
FilmArray™ Gastrointestinal (GI) Panel (Device)
Age
Pediatric, Adult
Sex
All
Sponsor
BioFire Diagnostics, LLC
Primary completion
Aug 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel
434; 19

Summary

BioFire Diagnostics, LLC (BioFire) has developed the FilmArray Gastrointestinal (GI) Panel, a rapid, easy to use PCR-based in vitro diagnostic test for the identification of 22 common microorganisms responsible for infectious gastroenteritis (http://filmarray.com/the-panels/) from a stool specimen collected in Cary Blair enteric transport media. The test was made available for sale in the US and EU following FDA clearance and CE marking in May, 2014. The FilmArray GI Panel offers improvements over conventional laboratory testing which include: reduced turnaround time from specimen to result, reduced laboratory labor costs, increased sensitivity and specificity relative to current clinical reference methods, and larger breadth of organism identification than is available using standard methods. Because of these attributes, the results from this test have the potential to enable clinicians to more accurately diagnose and treat GI illness in a reduced time frame. Collaborators at the University of Utah, Brown University/Lifespan, and BioFire Diagnostics have designed a study to evaluate health outcomes of pediatric subjects presenting to emergency departments with GI illness before and after establishing the FilmArray GI Panel as the standard of care method for stool pathogen analysis. It is hypothesized that the rapid (~ 1 hour turnaround time), sensitive, specific, and comprehensive results provided by the FilmArray GI Panel will allow clinicians to more rapidly diagnose GI illness, initiate appropriate therapy and provide guidance when compared to the pre-implementation period.

Eligibility Criteria

Inclusion Criteria

  • Children (<18 years) presenting to the ED or onsite urgent care center with symptoms of gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.)
  • Duration of symptoms at least 24 hours but < 14 days
  • Able to provide stool specimen at time of enrollment or within the next two calendar days
  • Parent or guardian able to provide permission and subject able to provide assent, if appropriate

Exclusion Criteria

  • Undefined onset of illness or symptoms for ≥14 days
  • Unable to complete questionnaire or give informed consent because of language barrier
  • Those unable to provide stool specimen at time of enrollment or within two calendar days
  • Previous enrollment in this study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02248285). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search